siponimod
Showing 1 - 25 of 32
Mayzent Onboarding of Secondary Progressive Multiple Sclerosis
Completed
- Secondary Progressive Multiple Sclerosis
-
Camperdown, New South Wales, Australia
- +1 more
Apr 19, 2023
Assessment of Pregnancy Outcomes in Patients Treated With
Recruiting
- Multiple Sclerosis
- Siponimod
-
La Jolla, CaliforniaNovartis Investigative Site
Jan 20, 2023
Multiple Sclerosis Trial (Siponimod)
Available
- Multiple Sclerosis
- Siponimod
- (no location specified)
Sep 13, 2022
Mayzent on SPMS Patients in a Long-term Non-interventional Study
Recruiting
- Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
- Siponimod
-
Baden, Aargau, Switzerland
- +8 more
May 16, 2022
Secondary Progressive Multiple Sclerosis Trial in Germany (BAF312, Baseline disease modifying therapies (DMTs))
Active, not recruiting
- Secondary Progressive Multiple Sclerosis
- BAF312
- Baseline disease modifying therapies (DMTs)
-
Mittweida, Sachsen, Germany
- +9 more
Aug 9, 2022
Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate
Recruiting
- Multiple Sclerosis
- Diroximel Fumarate
- +8 more
-
Eden Prairie, MinnesotaOptumInsight
Jan 9, 2023
Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy
Recruiting
- Active Secondary Progressive Multiple Sclerosis
- siponimod
-
Ancona, AN, Italy
- +19 more
Dec 27, 2022
Multiple Sclerosis, Relapsing-Remitting Trial in United Kingdom, United States (Early Highly Effective Therapies Group,
Recruiting
- Multiple Sclerosis, Relapsing-Remitting
- Early Highly Effective Therapies Group
- Escalation Therapies Group
-
Aurora, Colorado
- +30 more
Jul 22, 2022
Among Healthcare Professionals and MS Patients to Assess Their
Recruiting
- Multiple Sclerosis
-
Basel, SwitzerlandNovartis Investigative Site
Mar 21, 2022
COVID-19 Vaccine Response in Treated MS Patients
Recruiting
- Multiple Sclerosis
- Healthy
- Blood draw
-
Boston, MassachusettsBrigham MS Center
Jul 26, 2022
Phase III Trial With BAF312 in Secondary Progressive Multiple
Completed
- Secondary Progressive Multiple Sclerosis
- Blood Draw
- CSF collection by lumbar puncture (Optional)
-
Berkeley, California
- +12 more
Nov 5, 2020
results Surveillance for Mayzent in SPMS Patients
Recruiting
- Secondary Progressive Multiple Sclerosis (SPMS)
-
Anjo, Aichi, Japan
- +210 more
Dec 22, 2022
Relapsing Remitting Multiple Sclerosis Trial in Portland (3 mg Melatonin, 5 mg Melatonin)
Active, not recruiting
- Relapsing Remitting Multiple Sclerosis
- 3 mg Melatonin
- 5 mg Melatonin
-
Portland, OregonProvidence MS Center
May 5, 2022
Multiple Sclerosis COVID-19/Vaccination Treated With Ofatumumab
Completed
- Multiple Sclerosis
-
East Hanover, New JerseyNovartis
Jul 14, 2023
Multiple Sclerosis Trial in Boston (Electronic Pill Bottle)
Completed
- Multiple Sclerosis
- Electronic Pill Bottle
-
Boston, MassachusettsMassachusetts General Hospital
Jul 26, 2021
Early Patients Initiating Ofatumumab for Treatment of Multiple
Completed
- Multiple Sclerosis
- Ofatunumab
-
East Hanover, New JerseyNovartis Investigative Site
Nov 7, 2022
Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis Trial in Warsaw (Cladribine Subcutaneous Injection, 0.9% Chloride
Recruiting
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis
- Cladribine Subcutaneous Injection
- 0.9% Chloride Injection Sodium
-
Warsaw, Mazowieckie, PolandInstitute of Psychiatry and Neurology
Jul 26, 2023
Multiple Sclerosis, Relapsing-Remitting Trial in Chisinau (IMCY-0141, Placebo, Dimethyl Fumarate)
Recruiting
- Multiple Sclerosis, Relapsing-Remitting
- IMCY-0141
- +2 more
-
Chisinau, Moldova, Republic ofRepublican Clinical Hospital, ARENSIA Exploratory Medicine
Jun 8, 2022
Multiple Sclerosis, Relapsing-Remitting Trial in United States (Early Aggressive Therapy or Traditional Therapy)
Recruiting
- Multiple Sclerosis, Relapsing-Remitting
- Early Aggressive Therapy or Traditional Therapy
-
Birmingham, Alabama
- +51 more
Jan 23, 2023
Multiple Sclerosis Trial in Derby (Homologous booster, Heterologous booster)
Recruiting
- Multiple Sclerosis
- Homologous booster
- Heterologous booster
-
Derby, ConnecticutGriffin Hospital
Jan 23, 2022